Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
neprilysin inhibitor |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
C09DX04
|
| gptkbp:bioavailability |
60%
|
| gptkbp:brand |
gptkb:Entresto
|
| gptkbp:CASNumber |
gptkb:1369773-39-6
|
| gptkbp:combines |
gptkb:valsartan
|
| gptkbp:contraindication |
history of angioedema
concomitant ACE inhibitor use |
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:discoveredIn |
2014
|
| gptkbp:drugClass |
antihypertensive agent
|
| gptkbp:eliminationHalfLife |
1.4 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
gptkb:C24H29NO5
|
| https://www.w3.org/2000/01/rdf-schema#label |
sacubitril
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits neprilysin
|
| gptkbp:metabolism |
LBQ657
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:proteinBinding |
94-97%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
hypotension
renal impairment hyperkalemia angioedema |
| gptkbp:usedFor |
heart failure
|
| gptkbp:bfsParent |
gptkb:Entresto
|
| gptkbp:bfsLayer |
5
|